Your browser doesn't support javascript.
loading
No evidence for TSLP pathway activity in human breast cancer.
Ghirelli, Cristina; Sadacca, Benjamin; Reyal, Fabien; Zollinger, Raphaël; Michea, Paula; Sirven, Philémon; Pattarini, Lucia; Martínez-Cingolani, Carolina; Guillot-Delost, Maude; Nicolas, André; Scholer-Dahirel, Alix; Soumelis, Vassili.
Afiliación
  • Ghirelli C; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
  • Sadacca B; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut Curie, Paris, France; Statistics and Genome team of the
  • Reyal F; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut Curie, Paris, France; Department of Surgery, Institut Cu
  • Zollinger R; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
  • Michea P; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
  • Sirven P; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
  • Pattarini L; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
  • Martínez-Cingolani C; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
  • Guillot-Delost M; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
  • Nicolas A; Platform of Investigative Pathology of Biopathology Department, Curie Institute , Paris, France.
  • Scholer-Dahirel A; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
  • Soumelis V; U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France.
Oncoimmunology ; 5(8): e1178438, 2016 Aug.
Article en En | MEDLINE | ID: mdl-27622057
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncoimmunology Año: 2016 Tipo del documento: Article País de afiliación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncoimmunology Año: 2016 Tipo del documento: Article País de afiliación: Francia